- $231.78m
- $106.61m
Palisade Bio Q2 net loss widens on higher R&D costs
Brief: Palisade Bio Q2 EPS USD -0.05
Palisade Bio Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: Palisade Bio Inc - May Offer And Sell Up To $300 Million Of Securities - SEC Filing
Palisade Bio Q1 net loss widens on higher R&D costs
Brief: Palisade Bio Q1 EPS USD -0.05
U.S. STOCKS ON THE MOVE -Analog Devices, BridgeBio, TransDigm
Palisade Bio rises; bowel disease drug set for global conference spotlight
Brief: Palisade Bio Announces Two Abstracts Selected For Poster Presentations At Leading Global Inflammatory Bowel Disease Conferences
U.S. RESEARCH ROUNDUP-Expedia Group, Hasbro, Palisade Bio
Brief: Palisade Bio Strengthens Clinical Leadership Team With Appointment Of James Izanec
Brief: Palisade Bio Appoints Sharon Skare As Vice President, Global Head Of Clinical Operations
Brief: Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)
Brief: Palisade Bio Announces Pricing Of Upsized $120 Million Underwritten Public Offering Of Common Stock
Brief: Palisade Bio Announces Adjournment Of Special Meeting Of Stockholders Due To Lack Of Quorum
Brief: Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data
Brief: Palisade Bio Receives Health Canada Clearance For Phase 1B Trial Of Pali-2108 In Fibrostenotic Crohn’S Disease (Fscd)
Palisade Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Palisade Bio Inc expected to post a loss of 56 cents a share - Earnings Preview